Committee Advances Legislation Addressing Price Transparency, Insulin affordability, Diabetes Prevention, Biosimilars, Food safety, Prescription Drug Labeling and Compounding, and Workforce
July 22, 2026 | |
Committee Advances Legislation Addressing Price Transparency, Insulin affordability, Diabetes Prevention, Biosimilars, Food safety, Prescription Drug Labeling and Compounding, and Workforce
Today, the Senate Health, Education, Labor and Pensions (HELP) Committee convened a markup to consider the following legislation. All bills were favorably advanced to the Senate floor. S. 1414, Expedited Access to Biosimilar Act (manager’s amendment, section-by-section): The bill eliminates the requirement for biosimilar under development to conduct studies assessing immunogenicity, pharmacodynamics, or comparative clinical efficacy, in an effort to… (Slifer, July 22, 2026) #Nutrition, #Prescription Drugs, #Transparency, #Workforce
